jobs

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Harpoon Therapeutics Inc.

Harpoon Therapeutics Strengthens Leadership Team
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Announces Up to $150 Million Private Placement
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Tickers HARP
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News Instagram Instagram
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

922 Allowance Ave SE
Medicine Hat, AB T1A 3G7

Office hours: 8:30 a.m.-4:30 p.m. Monday to Friday, closed Saturday Sunday and statutory holidays.

[P] 403.527.1101
[F] 403-527-0737

Print Advertising: 403.528.5659
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2024 The Medicine Hat News